ERYTHROMYCIN capsule delayed release

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

Erythromycin (UNII: 63937KV33D) (Erythromycin - UNII:63937KV33D)

Inapatikana kutoka:

KAISER FOUNDATION HOSPITALS

INN (Jina la Kimataifa):

Erythromycin

Tungo:

Erythromycin 250 mg

Dawa ya aina:

PRESCRIPTION DRUG

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

ERYTHROMYCIN- ERYTHROMYCIN CAPSULE, DELAYED RELEASE
KAISER FOUNDATION HOSPITALS
----------
ERYTHROMYCIN
DELAYED-RELEASE
CAPSULES, USP
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of Erythromycin
Delayed-release Capsules and other antibacterial drugs, Erythromycin
Delayed-release Capsules
should be used only to treat or prevent infections that are proven or
strongly suspected to be caused by
bacteria.
DESCRIPTION
Erythromycin Delayed-release Capsules contain enteric coated pellets
of erythromycin base for oral
administration.
Each Erythromycin Delayed-release Capsule contains 250 milligrams of
erythromycin base.
INACTIVE INGREDIENTS
Cellulosic polymers, citrate ester, D&C Red No. 30, D&C Yellow No. 10,
magnesium stearate and
povidone. The capsule shell contains FD&C Blue No. 1, FD&C Red No. 3,
gelatin, and titanium
dioxide.
Erythromycin i s produced by a strain of _Saccharopolyspora erythaea_
(formerly _Streptomyces erythraeus_)
and belongs to the macrolide group of antibiotics. It is basic and
readily forms salts with acids but it is
the base which is microbiologically active. Erythromycin base is (3R*,
4S*, 5S*, 6R*, 7R*, 9R*, 11R*,
12R*, 13S*, 14R*)-4-[(2,6-
Dideoxy-3-C-methyl-3-O-methyl-α-L-_ribo_-hexopyranosyl)
oxy]-14-ethyl-
7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-_xylo_-
hexopyranosyl]oxy] oxacyclotetradecane-2,10-dione.
CLINICAL PHARMACOLOGY
Orally administered erythromycin base and its salts are readily
absorbed in the microbiologically active
form. Interindividual variations in the absorption of erythromycin
are, however, observed, and some
patients do not achieve acceptable serum levels. Erythromycin is
largely bound to plasma proteins, and
the freely dissociating bound fraction after administration of
erythromycin base represents 90% of the
total erythromycin absorbed. After absorption, erythromycin diffuses
readily into most body fluids. In
the absence of meaningeal inflammation, low concentrations are
normal